An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Orgovyx

Chemical Namerelugolix
Dosage FormTablets (oral; 120 mg)
Drug ClassReceptor antagonists
SystemMale reproductive
CompanyMyovant Sciences, Inc.
Approval Year2020

Indication

  • Indicated for the treatment of adult patients with advanced prostate cancer.
Last updated on 1/11/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Orgovyx (relugolix) Prescribing Information.2020Myovant Sciences, Inc., Brisbane, CA
Document TitleYearSource
Oral relugolix for androgen-deprivation therapy in advanced prostate cancer.2020The New England Journal of Medicine